Fig. 2.

mTOR is a positive regulator of xCT expression. a–d RT-qPCR in triplicate and immunoblotting analysis of mRNA and protein. mRNA data are presented as means ± SEM. *P < 0.05. **P < 0.01, ***P < 0.001. WT, Tsc2^−/− (a), or Pten^−/− (b) MEFs treated with or without 10 nM rapamycin (R) for 24 h were analyzed. c xCT in Tsc2-null ELT3 cell line and its human TSC2 revertant. d ELT3 and human breast cancer cell line DA-MB 468 were treated with or without 10 nM rapamycin for 24 h. e Kidney tumor tissue (T) and adjacent normal tissue (N) from a TSC patient were immunoblotted. f Immunoblotting of the pituitary glands of control and Ghrhr-Cre; Tsc1^LoxP/LoxP mice treated with or without rapamycin (R). g Immunofluorescence staining for xCT (red) in WT and Tsc1-sKO mouse skins. Nuclei were stained with DAPI (blue). (Scale bars: 50 μm). Pten^−/− MEFs were transfected with small interfering RNA against Raptor (h) or Rictor (i) for 48 h and then harvested for immunoblotting